Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors?
Introduction: Cyclin Dependent Kinase (CDK) 4–6 inhibitors are the recommended first-line treatment option for hormone-positive metastatic breast cancer (MBC). They show their effects by causing cell cycle arrest in G1-S phase. Neutropenia is the most common haematological side effect. In the litera...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Breast |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977624001516 |